Literature DB >> 15361844

Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.

Tomoo Iwakuma1, John M Parant, Mark Fasulo, Edwin Zwart, Tyler Jacks, Annemieke de Vries, Guillermina Lozano.   

Abstract

Mdm2 and its homolog Mdm4 inhibit the function of the tumor suppressor p53. Targeted disruption of either mdm2 or mdm4 genes in mice results in embryonic lethality that is completely rescued by concomitant deletion of p53, suggesting that deletion of negative regulators of p53 results in a constitutively active p53. Thus, these mouse models offer a unique in vivo system to assay the functional significance of different p53 modifications. Phosphorylation of serine 389 in murine p53 occurs specifically after ultraviolet-light-induced DNA damage, and phosphorylation of this site enhances p53 activity both in vitro and in vivo. Recently, mice with a serine to alanine substitution at serine 389 (p53S389A) in the endogenous p53 locus were generated. To examine the in vivo significance of serine 389 phosphorylation during embryogenesis, we crossed these mutant mice to mice lacking mdm2 or mdm4. The p53S389A allele did not alter the embryonic lethality of mdm2 or mdm4. Additional crosses to assay the effect of one p53S389A allele with a p53 null allele also did not rescue the lethal phenotypes. In conclusion, the phenotypes due to loss of mdm2 or mdm4 were not even partially rescued by p53S389A, suggesting that p53S389A is functionally wild type during embryogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361844     DOI: 10.1038/sj.onc.1207793

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  p21 delays tumor onset by preservation of chromosomal stability.

Authors:  Juan A Barboza; Geng Liu; Zhenlin Ju; Adel K El-Naggar; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-14       Impact factor: 11.205

2.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

Authors:  Tamara Terzian; Young-Ah Suh; Tomoo Iwakuma; Sean M Post; Manja Neumann; Gene A Lang; Carolyn S Van Pelt; Guillermina Lozano
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

3.  Mammary tumor modifiers in BALB/cJ mice heterozygous for p53.

Authors:  Joanna G Koch; Xiangjun Gu; Younghun Han; Adel K El-Naggar; Melissa V Olson; Daniel Medina; D Joseph Jerry; Anneke C Blackburn; Gary Peltz; Christopher I Amos; Guillermina Lozano
Journal:  Mamm Genome       Date:  2007-06-08       Impact factor: 2.957

4.  Genetic modeling of Li-Fraumeni syndrome in zebrafish.

Authors:  John M Parant; Stephen A George; Joseph A Holden; H Joseph Yost
Journal:  Dis Model Mech       Date:  2010 Jan-Feb       Impact factor: 5.758

5.  Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.

Authors:  Benjamin Gottschalk; Andreas Klein
Journal:  Mol Cell Biochem       Date:  2013-04-07       Impact factor: 3.396

6.  The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12.

Authors:  Shuting Jia; Lanjun Zhao; Wenru Tang; Ying Luo
Journal:  Int J Biol Sci       Date:  2012-04-18       Impact factor: 6.580

7.  Ubiquitination of human AP-endonuclease 1 (APE1) enhanced by T233E substitution and by CDK5.

Authors:  Carlos S Busso; Courtney M Wedgeworth; Tadahide Izumi
Journal:  Nucleic Acids Res       Date:  2011-07-03       Impact factor: 16.971

8.  Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases.

Authors:  Yun Zhang; Shunbin Xiong; Bin Liu; Vinod Pant; Francis Celii; Gilda Chau; Ana C Elizondo-Fraire; Peirong Yang; Mingjian James You; Adel K El-Naggar; Nicholas E Navin; Guillermina Lozano
Journal:  Nat Commun       Date:  2018-09-27       Impact factor: 14.919

Review 9.  Regulating tumor suppressor genes: post-translational modifications.

Authors:  Ling Chen; Shuang Liu; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2020-06-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.